After a substantial drop in 2020, the total number of 1933 Act filings in connection with registered offerings further declined slightly (3%) in 2021. As in 2020, there also were a significant number of class actions filings related to the COVID-19 pandemic in 2021 - i.e., filings against companies that were particularly impacted by the pandemic or companies involved in the development of products (e.g., therapeutics, vaccines, and testing products) to address COVID-19 - although the number of COVID-19-related cases dropped significantly in the second half of 2021. Given the enormous volume of special purpose acquisition company (“SPAC”) initial public offerings and transactions over the last two or so years, “core” class action filings related to SPACs not surprisingly increased more than sixfold from 2020 to 2021. This decline was largely due to a dramatic drop (82%) in M&A-related class action filings, but was also due to a 17% decline in federal “core” class action filings alleging Rule 10b-5 claims under the 1934 Act. Securities Class Action Filings Across All Industries in 2021 -įor the first time in many years, in 2021, the number of new securities class action filings in federal and state courts dropped precipitously, falling from 333 actions in 2020 to 218 filings in 2021 - a 35% drop and below the 1997-2020 average of 228 actions. Plaintiffs typically assert claims under Sections 10(b), 20(a) and Rule 10b-5 of the Securities Exchange Act of 1934 (the “1934 Act”) based upon allegedly false and misleading statements or omissions made by the company and its officers, and/or, if the alleged misstatements or omissions are made in connection with a registered securities offering, under Sections 11, 12(a)(2) and 15 of the Securities Act of 1933 (the “1933 Act”).
These cases are typically filed by shareholders, on behalf of a putative class, seeking to recover investment losses after a company’s stock price drops following the disclosure of a setback or problem experienced by the company with respect to its drugs or products, such as negative feedback from or action by FDA, clinical trial delays, suspensions or terminations, negative clinical data results, adverse events experienced by patients, or manufacturing problems.
We are proud to present our sixth annual Securities Litigation Year in Review publication, in which we analyze data for securities class actions filed nationally against publicly traded pharmaceutical, biotechnology, medical device and healthcare product and services companies (collectively referred to herein as “life sciences companies”) and summarize important decisions issued by courts in 2021 in key jurisdictions in these cases.
Summary of 2021 Trends, Themes, and Takeaways.
0 kommentar(er)
